Health & Environmental Research Online (HERO)


Print Feedback Export to File
4234856 
Journal Article 
Cellular accumulation and lipid binding of perfluorinated alkylated substances (PFASs) - A comparison with lysosomotropic drugs 
Sanchez Garcia, D; Sjödin, M; Hellstrandh, M; Norinder, U; Nikiforova, V; Lindberg, J; Wincent, E; Bergman, Å; Cotgreave, I; Munic Kos, V 
2018 
Yes 
Chemico-Biological Interactions
ISSN: 0009-2797
EISSN: 1872-7786 
ELSEVIER IRELAND LTD 
CLARE 
281 
1-10 
English 
Many chemicals accumulate in organisms through a variety of different mechanisms. Cationic amphiphilic drugs (CADs) accumulate in lysosomes and bind to membranes causing phospholipidosis, whereas many lipophilic chemicals target adipose tissue. Perfluoroalkyl substances (PFASs) are widely used as surfactants, but many of them are highly bioaccumulating and persistent in the environment, making them notorious environmental toxicants. Understanding the mechanisms of their bioaccumulation is, therefore, important for their regulation and substitution with new, less harmful chemicals. We compared the highly bioaccumulative perfluorooctanesulfonic acid PFOS to its three less bioaccumulative alternatives perfluorooctanoic acid (PFOA), perfluorohexanoic acid (PFHxA) and perfluorobutane sulfonic acid (PFBS), in their ability to accumulate and remain in lung epithelial cells (NCI-H292) and adipocytes (3T3-L1K) in vitro. As a reference point we tested a set of cationic amphiphilic drugs (CADs), known to highly accumulate in cells and strongly bind to phospholipids, together with their respective non-CAD controls. Finally, all compounds were examined for their ability to bind to neutral lipids and phospholipids in cell-free systems. Cellular accumulation and retention of the test compounds were highly correlated between the lung epithelial cells and adipocytes. Interestingly, although an anion itself, intensities of PFOS accumulation and retention in cells were comparable to those of CAD compounds, but PFOS failed to induce phospholipidosis or alter lysosomal volume. Compared to other lipophilicity measures, phospholipophilicity shows the highest correlation (Rˆ2 = 0.75) to cellular accumulation data in both cell types and best distinguishes between high and low accumulating compounds. This indicates that binding to phospholipids may be the most important component in driving high cellular accumulation in lung epithelial cells, as well as in adipocytes, and for both CADs and bioaccumulating PFASs. Obtained continuous PLS models based on compound's affinity for phospholipids and neutral lipids can be used as good prediction models of cellular accumulation and retention of PFASs and CADs. 
Bioaccumulation; Perfluorinated compounds; PFOS; Cationic amphiphilic drugs; Adipocytes; Phospholipid binding 
PFAS
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          Other Sources
               TEDX
     Screened Studies
          Excluded
               Exclude (TIAB)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
          Other Sources
               PFAS TOX Database
     Screened Studies
          Excluded
               Exclude (TIAB)
     Not prioritized for screening
     Perfluorooctane
     Potassium perfluorooctanoate
     Sodium perfluorooctanoate
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
          ToxNet
          Other sources
               PFAS TOX Database
     Not prioritized for screening
     Ammonium perfluorooctanoate
     Perfluorinated compounds
     Perfluorobutanesulfonic acid
     Perfluorobutanesulfonyl fluoride
     Perfluorohexanoic acid
     Perfluorooctane
     Perfluorooctanesulfonic acid
     Perfluorooctanoic acid
     1,1,1,3,3,3-Hexafluoro-2- (fluoromethoxy)propane
• PFBS
          Excluded/Not on Topic
     Search
          PubMed
          WOS
     Excluded
          PubMed
          WOS
     Scopus: April 2021
• PFHxA
     LitSearch Update: February 2018
          PubMed
          Toxline
          WoS
     Literature Search
          Pubmed
          Toxline
          WOS
     Scopus: April 2021
     Title and Abstract Screening
          Full Text Screening
          Tagged as Supplemental
               ADME TK
     Results pulled from Pelch database May 2022
     HAWC
• PFHxS
• PFNA
     Litsearch Update 2017-2018
          PFAS Untag
     Literature Search
          Toxline
     PFNA May 2019 Update
          Toxnet
     Title and Abstract Screening
          Full Text Screening
               Excluded
                    Not PFNA
          Tagged as Supplemental
               Mechanistic or MOA
               ADME
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search Update (2013-2019)
          PubMed
          WOS
• PFOA and PFOS OW MCLG Approaches
     Cited in White Papers